JP2020523319A - 免疫調節化合物の抗体コンジュゲートおよびその使用 - Google Patents

免疫調節化合物の抗体コンジュゲートおよびその使用 Download PDF

Info

Publication number
JP2020523319A
JP2020523319A JP2019567691A JP2019567691A JP2020523319A JP 2020523319 A JP2020523319 A JP 2020523319A JP 2019567691 A JP2019567691 A JP 2019567691A JP 2019567691 A JP2019567691 A JP 2019567691A JP 2020523319 A JP2020523319 A JP 2020523319A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523319A5 (enExample
Inventor
ピーター アームストロング トンプソン，
ピーター アームストロング トンプソン，
バドレディン エドリス，
バドレディン エドリス，
クレイグ アラン コバーン，
クレイグ アラン コバーン，
ピーター ロバート バウム，
ピーター ロバート バウム，
ヴァレリー オデガード，
ヴァレリー オデガード，
Original Assignee
シルバーバック セラピューティックス インコーポレイテッド
シルバーバック セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シルバーバック セラピューティックス インコーポレイテッド, シルバーバック セラピューティックス インコーポレイテッド filed Critical シルバーバック セラピューティックス インコーポレイテッド
Publication of JP2020523319A publication Critical patent/JP2020523319A/ja
Publication of JP2020523319A5 publication Critical patent/JP2020523319A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019567691A 2017-06-07 2018-06-07 免疫調節化合物の抗体コンジュゲートおよびその使用 Pending JP2020523319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516638P 2017-06-07 2017-06-07
US62/516,638 2017-06-07
PCT/US2018/036554 WO2018227018A1 (en) 2017-06-07 2018-06-07 Antibody conjugates of immune-modulatory compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2020523319A true JP2020523319A (ja) 2020-08-06
JP2020523319A5 JP2020523319A5 (enExample) 2021-07-26

Family

ID=64567206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567691A Pending JP2020523319A (ja) 2017-06-07 2018-06-07 免疫調節化合物の抗体コンジュゲートおよびその使用

Country Status (7)

Country Link
US (1) US20200199247A1 (enExample)
EP (1) EP3634485A4 (enExample)
JP (1) JP2020523319A (enExample)
CN (1) CN110891605A (enExample)
AU (1) AU2018279105A1 (enExample)
CA (1) CA3065852A1 (enExample)
WO (1) WO2018227018A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509760A (ja) * 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
JP2023541853A (ja) * 2020-09-08 2023-10-04 ユーティレックス カンパニー リミテッド Ｐｄ－１ポリペプチド変異体
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3802518A1 (en) * 2018-05-25 2021-04-14 Silverback Therapeutics, Inc. Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220008306A (ko) * 2019-05-10 2022-01-20 리브젠 바이오파마 코., 엘티디. 인간화 항-cd137 항체 및 이의 용도
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
TWI845724B (zh) * 2019-07-19 2024-06-21 大陸商上海藥明合聯生物技術有限公司 用於偶聯的多肽複合物及其應用
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
WO2021102332A1 (en) * 2019-11-22 2021-05-27 Silverback Therapeutics, Inc. Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
AU2020402752A1 (en) * 2019-12-12 2022-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for CD276 and uses thereof
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021202642A2 (en) * 2020-04-01 2021-10-07 The Regents Of The University Of California Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2021231922A1 (en) * 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
US20230212282A1 (en) * 2020-05-29 2023-07-06 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis
AU2021283279A1 (en) * 2020-06-02 2023-01-19 Children's Medical Center Corporation Nanobody (VHH) conjugates and uses there of
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
KR102506295B1 (ko) * 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
CN114146095A (zh) * 2020-09-07 2022-03-08 是光隽恒(北京)生物科技有限公司 用于组织损伤修复的组合物及其制备方法和用途
US20240010722A1 (en) * 2020-11-18 2024-01-11 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
JP2024526259A (ja) 2021-07-02 2024-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｒｏｔａｃ抗体および複合体
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US20250043005A1 (en) * 2021-12-09 2025-02-06 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
WO2023125121A1 (zh) * 2021-12-30 2023-07-06 四川科伦博泰生物医药股份有限公司 一类三并环化合物、其制备方法及用途
TW202432187A (zh) * 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
EP4642482A1 (en) 2022-12-27 2025-11-05 Merck Patent GmbH Vhh anti-protac antibodies and complexes
FR3147292A1 (fr) * 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
FR3147278A1 (fr) * 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
CN121013863A (zh) * 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 Tnfr2结合多肽及使用方法
TW202500195A (zh) * 2023-05-18 2025-01-01 美商飛爾富來生物公司 異吲哚啉酮－戊二醯亞胺抗體結合物及其用途
WO2024243545A1 (en) * 2023-05-24 2024-11-28 President And Fellows Of Harvard College Compositions targeting endothelial cells and uses thereof
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025163120A1 (en) * 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
EP4595981A1 (en) * 2024-02-01 2025-08-06 Jack Elands Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025216667A1 (en) * 2024-04-12 2025-10-16 Joint Stock Company «Biocad» Monoclonal antibody that specifically binds to bdca-2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506664A (ja) * 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
JP2014519807A (ja) * 2011-04-29 2014-08-21 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート
US20150151344A1 (en) * 2012-01-26 2015-06-04 Yorozu Corporation Method for manufacturing curved hollow pipe
US20170080103A1 (en) * 2014-05-22 2017-03-23 Synthon Biopharmaceutical B.V. Site-specific conjugation of linker drugs to antibodies and resulting adcs
US20170151343A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088004B1 (en) * 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
MX394449B (es) * 2012-01-12 2025-03-11 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016365117A1 (en) * 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
WO2019195278A1 (en) * 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
EP3802518A1 (en) * 2018-05-25 2021-04-14 Silverback Therapeutics, Inc. Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506664A (ja) * 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
JP2014519807A (ja) * 2011-04-29 2014-08-21 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート
US20150151344A1 (en) * 2012-01-26 2015-06-04 Yorozu Corporation Method for manufacturing curved hollow pipe
US20170080103A1 (en) * 2014-05-22 2017-03-23 Synthon Biopharmaceutical B.V. Site-specific conjugation of linker drugs to antibodies and resulting adcs
US20170151343A1 (en) * 2015-11-30 2017-06-01 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol. 6, Issue 2, e56442, JPN6022013621, 2013, pages 1 - 9, ISSN: 0004748502 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509760A (ja) * 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
JP2023541853A (ja) * 2020-09-08 2023-10-04 ユーティレックス カンパニー リミテッド Ｐｄ－１ポリペプチド変異体
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof

Also Published As

Publication number Publication date
AU2018279105A1 (en) 2019-12-19
EP3634485A1 (en) 2020-04-15
EP3634485A4 (en) 2021-07-21
CN110891605A (zh) 2020-03-17
CA3065852A1 (en) 2018-12-13
US20200199247A1 (en) 2020-06-25
WO2018227018A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP2020523319A (ja) 免疫調節化合物の抗体コンジュゲートおよびその使用
JP2022500404A (ja) 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
EP3634401A1 (en) Antibody construct conjugates
KR20200031560A (ko) 벤즈아제핀 화합물, 접합체, 및 그의 용도
WO2021011834A1 (en) Alk5 inhibitors, conjugates, and uses thereof
JP2021525799A (ja) アミノ−ピラジンカルボキサミド化合物、コンジュゲート、およびそれらの使用
US20210154317A1 (en) Compositions and methods for the treatment of viral infections
WO2018140831A2 (en) Tumor targeting conjugates and methods of use thereof
WO2017100305A2 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
CA3049842A1 (en) Construct-peptide compositions and methods of use thereof
CA3131104A1 (en) Cyclic amino-pyrazinecarboxamide compounds and uses thereof
WO2022006340A1 (en) Alk5 inhibitors, conjugates, and uses thereof
WO2022076905A1 (en) Alk5 inhibitors, conjugates, and uses thereof
CN111867621A (zh) 用于耗尽cd134+细胞的组合物和方法
GB2552041A (en) Compositions of antibody construct-agonist conjugates and methods thereof
HK40021778A (en) Benzazepine compounds, conjugates, and uses thereof
HK40021778B (en) Benzazepine compounds, conjugates, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221108